Answers are grounded in this paper and cite their sources.
Host lymphodepletion followed by autologous TIL transfer and IL-2 results in objective response rates of 50% to 70% in patients with metastatic melanoma refractory to standard therapies.
No takes yet. Share an insight, caveat, or question.
Dudley et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: